Literature DB >> 28059083

Behavioral Determinants of Cannabinoid Self-Administration in Old World Monkeys.

William S John1, Thomas J Martin2, Michael A Nader1.   

Abstract

Reinforcing effects of Δ9-tetrahydrocannabinol (THC), the primary active ingredient in marijuana, as assessed with self-administration (SA), has only been established in New World primates (squirrel monkeys). The objective of this study was to investigate some experimental factors that may enhance intravenous SA of THC and the cannabinoid receptor (CBR) agonist CP 55 940 in Old World monkeys (rhesus and cynomolgus), a species that has been used extensively in biomedical research. In one experiment, male rhesus monkeys (N=9) were trained to respond under a fixed-ratio 10 schedule of food presentation. The effects of CP 55 940 (1.0-10 μg/kg, i.v.) and THC (3.0-300 μg/kg, i.v.) on food-maintained responding and body temperature were determined in these subjects prior to giving them access to self-administer each drug. Both drugs dose-dependently decreased food-maintained responding. CP 55 940 (0.001-3.0 μg/kg) functioned as a reinforcer in three monkeys, whereas THC (0.01-10 μg/kg) did not have reinforcing effects in any subject. CP 55 940 was least potent to decrease food-maintained responding in the monkeys in which CP 55 940 functioned as a reinforcer. Next, THC was administered daily to monkeys until tolerance developed to rate-decreasing effects. When THC SA was reexamined, it functioned as a reinforcer in three monkeys. In a group of cocaine-experienced male cynomolgus monkeys (N=4), THC SA was examined under a second-order schedule of reinforcement; THC functioned as reinforcer in two monkeys. These data suggest that SA of CBR agonists may be relatively independent of their rate-decreasing effects in Old World monkeys. Understanding individual differences in vulnerability to THC SA may lead to novel treatment strategies for marijuana abuse.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28059083      PMCID: PMC5436120          DOI: 10.1038/npp.2017.2

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  39 in total

1.  3H-delta9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs.

Authors:  B R Martin; W L Dewey; L S Harris; J S Beckner
Journal:  J Pharmacol Exp Ther       Date:  1976-01       Impact factor: 4.030

2.  Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Authors:  Timothy W Lefever; Julie A Marusich; Kateland R Antonazzo; Jenny L Wiley
Journal:  Pharmacol Biochem Behav       Date:  2014-01-09       Impact factor: 3.533

3.  Blood levels of 3 H- 9 -tetrahydrocannabinol and its metabolites in tolerant and nontolerant pigeons.

Authors:  D E McMillan; W L Dewey; R F Turk; L S Harris; J H McNeil
Journal:  Biochem Pharmacol       Date:  1973-02-01       Impact factor: 5.858

4.  Reinforcements from the first drug experience can predict later drug habits and/or addiction: results with coffee, cigarettes, alcohol, barbiturates, minor and major tranquilizers, stimulants, marijuana, hallucinogens, heroin, opiates and cocaine.

Authors:  C A Haertzen; T R Kocher; K Miyasato
Journal:  Drug Alcohol Depend       Date:  1983-04       Impact factor: 4.492

5.  Intravenous self-administration of drugs in rats.

Authors:  J M van Ree; J L Slangen; D de Wied
Journal:  J Pharmacol Exp Ther       Date:  1978-03       Impact factor: 4.030

6.  Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.

Authors:  Jennifer L Stewart; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2010-04-07       Impact factor: 4.030

7.  A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice.

Authors:  E Valjent; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

8.  Differential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeys.

Authors:  William S John; Amy Hauck Newman; Michael A Nader
Journal:  Neuropharmacology       Date:  2015-01-06       Impact factor: 5.250

9.  Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.

Authors:  F Fan; D R Compton; S Ward; L Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

10.  Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.

Authors:  Brian D Kangas; Michael Z Leonard; Vidyanand G Shukla; Shakiru O Alapafuja; Spyros P Nikas; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2016-01-29       Impact factor: 4.030

View more
  15 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

2.  Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures.

Authors:  David R Maguire; Charles P France
Journal:  Drug Alcohol Depend       Date:  2020-05-12       Impact factor: 4.492

3.  Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.

Authors:  J A Suyama; M L Banks; S S Negus
Journal:  Psychopharmacology (Berl)       Date:  2018-09-19       Impact factor: 4.530

4.  Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats.

Authors:  Krista J Spiller; Guo-Hua Bi; Yi He; Ewa Galaj; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Br J Pharmacol       Date:  2019-04-03       Impact factor: 8.739

5.  Chronic Δ9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability.

Authors:  William S John; Thomas J Martin; Kiran Kumar Solingapuram Sai; Susan H Nader; H Donald Gage; Akiva Mintz; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2017-12-04       Impact factor: 4.030

Review 6.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

Review 7.  Utility of Nonhuman Primates in Substance Use Disorders Research.

Authors:  Matthew L Banks; Paul W Czoty; Sidney S Negus
Journal:  ILAR J       Date:  2017-12-01

Review 8.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

Review 9.  Progress in brain cannabinoid CB2 receptor research: From genes to behavior.

Authors:  Chloe J Jordan; Zheng-Xiong Xi
Journal:  Neurosci Biobehav Rev       Date:  2019-01-03       Impact factor: 8.989

Review 10.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.